Free tool
Drugs in development
Last checked: Nov 20, 2026Latest source record: rebuilt Nov 18, 2026Source: ClinicalTrials.govMethods & limitations
Drugs in development
3,685
Not FDA-approved
In Phase 3
1,424
Highest phase reached
Matching your filters
3,685
3,685 drugs in development
Names, sponsors and conditions come from the trial records. Click a drug for its trials.
- ALK202Phase 21 trial
Shanghai Allink Biotherapeutics Co., Ltd. · NSCLC (Advanced Non-small Cell Lung Cancer)
- ALKS 7290Phase 21 trial
Alkermes, Inc. · Attention Deficit Disorder With Hyperactivity (ADHD)
- ALLO-647Phase 21 trial
Allogene Therapeutics · Relapsed or Refractory Large B Cell Lymphoma, Relapsed or Refractory Chronic Lymphocytic Leukemia, Relapsed or Refractory Small Lymphocytic Lymphoma
- ALMB-0168Phase 21 trial
AlaMab Therapeutics (Shanghai) Inc. · Advanced Solid Tumors With Bone Only Metastasis
- ALN-2232Phase 21 trial
Alnylam Pharmaceuticals · Obesity
- ALN-6457ALN-PRNPPhase 21 trial
Regeneron · Prion Disease
- Alomnertinib MesilatePhase 21 trial
Shanghai Hengrui Pharmaceutical Co., Ltd. · Non-small Cell Lung Cancer
- Alpe375Phase 21 trial
BioVersys AG · Tuberculosis Meningitis
- AlpE500Phase 21 trial
BioVersys AG · Tuberculosis Meningitis
- AlpE625Phase 21 trial
BioVersys AG · Tuberculosis Meningitis
- ALT-100Phase 21 trial
Aqualung Therapeutics Corp. · Acute Respiratory Distress Syndrome (ARDS)
- ALTB-268Phase 21 trial
AltruBio Inc. · Ulcerative Colitis
- ALTO-100Phase 21 trial
Alto Neuroscience · Bipolar Disorder I or II With a Major Depressive Episode
- ALTO-101Phase 21 trial
Alto Neuroscience · Schizophrenia, Cognitive Impairment
- ALTO-203Phase 21 trial
Alto Neuroscience · Major Depressive Disorder, Anhedonia
- ALTO-207Phase 21 trial
Alto Neuroscience · Treatment-resistant Depression (TRD)
- ALTO-300Phase 21 trial
Alto Neuroscience · Major Depressive Disorder
- ALV-100Phase 21 trial
Alveus Therapeutics, Inc. · Overweight , Obesity, Adults
- ALXN1920Phase 21 trial
AstraZeneca · Primary Membranous Nephropathy
- ALXN2030Phase 21 trial
AstraZeneca · Antibody-Mediated Rejection, Kidney Transplantation, Biopsy-proven Histologic Scores
- ALXN2350Phase 21 trial
AstraZeneca · BAG3 Mutation Associated Dilated Cardiomyopathy
- ALZN002autologous DCs pulsed with E22W mutant peptidePhase 21 trial
Alzamend Neuro, Inc. · Alzheimer Disease
- AMC6156Phase 21 trial
Animuscure Inc. · Sarcopenia in Elderly, Sarcopenia
- AMO959BY1298, BY101298Phase 21 trial
Novartis · PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy
- AMP945Phase 21 trial
Amplia Therapeutics Limited · Pancreatic Cancer, PDAC, Pancreatic Ductal Adenocarcinoma
- amsulostatPXS-5505Phase 21 trial
Syntara · Myelofibrosis, Primary Myelofibrosis (PMF), Post- Essential Thrombocythemia Myelofibrosis
- AMT-143Phase 21 trial
AmacaThera Inc. · Bunionectomy, Bunion
- AMT-162Phase 21 trial
UniQure Biopharma B.V. · Amyotrophic Lateral Sclerosis
- AMT-191Phase 21 trial
UniQure Biopharma B.V. · Fabry Disease
- AMT-253Phase 21 trial
Multitude Therapeutics Inc. · Malignant Melanoma, Advanced Solid Tumors
- AMT-676Phase 21 trial
Multitude Therapeutics Inc. · Colorectal Cancer
- AMXI-5001Phase 21 trial
AtlasMedx, Incorporated · Advanced Malignant Neoplasm, Breast Cancer, Ovarian Cancer
- and CarboplatinPhase 21 trial
CrystalGenomics, Inc. · Non Squamous Non Small Cell Lung Cancer
- ANG003Phase 21 trial
Anagram Therapeutics, Inc. · Exocrine Pancreatic Insufficiency (EPI), Cystic Fibrosis (CF)
- ANO31905Phase 21 trial
Anova Innovation Limited · Pancreatic Cancer
- ANS014004Phase 21 trial
Beijing Pearl Biotechnology Limited Liability Company · Non-Small Cell Lung Cancer, EGFR Mutation, Metastatic Lung Cancer
- ANS02Phase 21 trial
Avistone Biotechnology Co., Ltd. · Non-Small Cell Lung Cancer
- AnumigilimabPhase 21 trial
CSL Behring · Sickle Cell Disease
- ANV600Phase 21 trial
Anaveon AG · Advanced Solid Tumor
- AP-101Phase 21 trial
AL-S Pharma · Amyotrophic Lateral Sclerosis
- AP-472Phase 21 trial
Appello Pharmaceuticals, Inc. · Parkinson Disease
- AP02Phase 21 trial
Avalyn Pharma Inc. · Idiopathic Pulmonary Fibrosis (IPF)
- AP203Phase 21 trial
AP Biosciences Inc. · Locally Advanced or Metastatic Solid Tumors, Non Small Cell Lung Cancer (NSCLC), Head and Neck Squamous Cell Carcinoma (HNSCC)
- AP306Phase 21 trial
R1 Therapeutics · Hyperphosphatemia, Chronic Kidney Disease Requiring Chronic Dialysis, End Stage Renal Disease on Dialysis
- AP31969Phase 21 trial
Acesion Pharma · Atrial Fibrillation (AF)
- AP402Phase 21 trial
AP Biosciences Inc. · Advanced Solid Tumor
- APHD-002Phase 21 trial
Aphaia Pharma US LLC · Obese With Comorbidities, Obese Patients (BMI ≥ 30 kg/m²)
- APHD-012Phase 21 trial
Aphaia Pharma US LLC · Obese With Comorbidities, Obese Patients (BMI ≥ 30 kg/m²)
- APHP-002Phase 21 trial
Aphaia Pharma US LLC · Obese With Comorbidities, Obese Patients (BMI ≥ 30 kg/m²)
- APHP-012Phase 21 trial
Aphaia Pharma US LLC · Obese With Comorbidities, Obese Patients (BMI ≥ 30 kg/m²)
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.